Kambô, an Amazonian frog's skin secretion applied to small burns, is promoted as a cleanse, mood aid and immune tonic. It triggers a violent but usually brief purge. Evidence for benefit is thin: surveys of volunteer users report better well-being and less alcohol and drug use. Case reports describe serious harms of unknown frequency, including dangerous drops in blood sodium, seizures, sudden heart-related death and tearing of the esophagus. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Serum sodium | 135–145 mmol/L | Safety check: a low value stops use |
| Serum potassium | 3.5–5.0 mmol/L | Safety check: a low value stops use |
| Resting ECG (rhythm and QTc) | Sinus rhythm; QTc below 450 ms in men and 460 ms in women | Safety check: an abnormal rhythm or prolonged QTc stops use |
| ALT | Up to about 40 U/L | Safety check: a rise stops use |
| Serum creatinine | About 0.6–1.2 mg/dL | Safety check: a rise stops use |
| Creatine kinase | About 30–200 U/L | Safety check: a marked rise signals muscle breakdown and stops use |
| hCG | Negative | Safety check: a positive result stops use |
| Plasma and urine osmolality | Not specified in the ER | Paired with sodium to identify water retention by the kidneys |
| Magnesium | Not specified in the ER | Paired with potassium |
| AST | Not specified in the ER | Paired with ALT; liver and muscle enzyme |
| eGFR | Not specified in the ER | Paired with creatinine; kidney filtration |
Cadence: Baseline panel before a first session; sodium within 2–6 hours after any session with persistent vomiting, headache, confusion or weakness; repeat panel at 24–48 hours if symptoms continue; hCG before each session; ECG repeated if palpitations or fainting occur after a session; creatine kinase after seizures or prolonged weakness; full baseline panel before each new session series, or every 3–6 months for repeated users.